Global Health / Health Policy / Logistic Regression / Humans / United States / Regression Analysis / Income / Least Developed Countries / Socioeconomic Status / Public health systems and services research / Drug Costs / World Health Organization / Universal Access / Linear Regression / Drug Industry / Logistic Regression Model / Linear Regression Model / Regression Analysis / Income / Least Developed Countries / Socioeconomic Status / Public health systems and services research / Drug Costs / World Health Organization / Universal Access / Linear Regression / Drug Industry / Logistic Regression Model / Linear Regression Model
Marketing / Applied Economics / Spain / Humans / Generic Drugs / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies
Marketing / Applied Economics / Spain / Humans / Generic Drugs / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies / Economic Competition / Public health systems and services research / Drug Costs / Pharmacies
Primary Care / Primary Health Care / Public Health / Quality Control / Spain / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record
Primary Care / Primary Health Care / Public Health / Quality Control / Spain / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record / Pharmaceutical industry / Humans / Cost effectiveness / National Health Service / Case Management / Government Agencies / Self medication / Patient Care / Cost Benefit Analysis / Drug Costs / Polypharmacy / Low Risk / Health Priorities / Drug Utilization / Electronic Medical Record
Spain / Stroke / Humans / Female / Atrial Fibrillation / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles / Anticoagulants / Aged / Middle Aged / Budgets / Public health systems and services research / Cost Benefit Analysis / Drug Costs / Benzimidazoles